" class="no-js "lang="en-US"> Peter Hamley - Medtech Alert
Thursday, March 30, 2023

Breaking News

Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Implantica Launches RefluxStop™ in Italy Granular Therapeutics to Accelerate Development of Next-Generation Pipeline for Treating Mast Cell Driven Diseases Xeris Biopharma Appoints Ricki Fairley to Board of Directors AskBio to Present Phase 1b Results Investigating AB-1005 as Treatment for Parkinson’s Disease New Imaging Method for Evaluating Transport of Oxygen to Blood Cells
Peter Hamley

Peter Hamley

About Peter Hamley

Experienced leader and manager in complex cross-functional R&D and BD organisations of big pharma and biotech, with a track record of consistent value creation, building world-leading high technology groups, delivering drugs into development and establishing new external business models.

Related Story

Appointments

 Samsara Therapeutics Establishes Scientific Advisory Board | Pharmtech Focus

Samsara Therapeutics Establishes Scientific Advisory Board

January 6 2022

Samsara Therapeutics Inc. (Samsara), a discovery-stage biotech with a world-leading screening platform for inducers of […]